Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $13.1 million.

  • Ligand Pharmaceuticals' Free Cash Flow fell 6420.75% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.7 million, marking a year-over-year increase of 844991.83%. This contributed to the annual value of $95.2 million for FY2024, which is 10676.13% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Free Cash Flow stood at $13.1 million for Q3 2025, which was down 6420.75% from $15.6 million recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Free Cash Flow peaked at $101.6 million during Q4 2024, and registered a low of -$61.6 million during Q2 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' median Free Cash Flow value was $16.2 million (recorded in 2022), while the average stood at $17.6 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Free Cash Flow surged by 242817.93% in 2021, and later crashed by 2150736.84% in 2024.
  • Ligand Pharmaceuticals' Free Cash Flow (Quarter) stood at $25.4 million in 2021, then soared by 101.76% to $51.3 million in 2022, then crashed by 85.1% to $7.6 million in 2023, then surged by 1229.11% to $101.6 million in 2024, then tumbled by 87.14% to $13.1 million in 2025.
  • Its last three reported values are $13.1 million in Q3 2025, $15.6 million for Q2 2025, and -$25.7 million during Q1 2025.